AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30860588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 79
Study 28630086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation therapy specifically adapted for Parkinson's‐related dementias (CST‐PD), involving 30 min sessions delivered at home by the study companion three times per week over 10 weeks.
Number of subjects: 0
Study 28630086 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 25224595 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) combined with Caphosol(®)
Number of subjects: 40
Study 25224595 — intervention group
Group type: COMPARATOR
Intervention: Oral cryotherapy (OC) only
Number of subjects: 40
Study 23834543 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lifestyle activity modification (LAM)
Number of subjects: 16
Study 23834543 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 21209397 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg qd
Number of subjects: 85
Study 21209397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg bid
Number of subjects: 85
Study 21209397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose‐enriched inulin (ORAFTI®Synergy1) 6 gm bid
Number of subjects: 85
Study 21209397 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin) 6 gm bid
Number of subjects: 85
Study 19232138 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Communication Program (TCom)
Number of subjects: 79
Study 19232138 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (February group)
Number of subjects: 79
Study 17065895 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine
Number of subjects: 29
Study 17065895 — intervention group
Group type: COMPARATOR
Intervention: Perineural normal saline
Number of subjects: 29
Study 12921454 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery and relaxation therapy
Number of subjects: 10
Study 10763948 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized multicomponent behavioral therapy plus standard medical treatment (SMBT)
Number of subjects: 24
Study 10763948 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment alone (SMT)
Number of subjects: 24
Study 8610798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelli‐Robson contrast sensitivity
Number of subjects: 438
Study 8610798 — intervention group
Group type: EXPERIMENTAL
Intervention: Snellen visual acuity
Number of subjects: 438
Study 8610798 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey Field Analyzer mean deviation
Number of subjects: 438
Study 8610798 — intervention group
Group type: EXPERIMENTAL
Intervention: Farnsworth‐Munsell 100‐hue color vision
Number of subjects: 438
Study 1376586 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense supplementary food with nutrition education
Number of subjects: 0
Study 1376586 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education alone (Control)
Number of subjects: 0
Study 6145368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg intravenously
Number of subjects: 24
Study 6145368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg intravenously
Number of subjects: 24
Study 3730522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination ('Tenoret 50')
Number of subjects: 12
Study 3730522 — intervention group
Group type: COMPARATOR
Intervention: Free combination
Number of subjects: 12
Study 3730522 — intervention group
Group type: COMPARATOR
Intervention: Atenolol tablet
Number of subjects: 12
Study 3730522 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone tablet
Number of subjects: 12
Study 30073285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50% nitrous oxide and 50% oxygen inhaled for 40 minutes)
Number of subjects: 40
Study 30073285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50% nitrogen and 50% oxygen inhaled for 40 minutes)
Number of subjects: 40
Study 30073285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 40
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial nerve injury (CNI) in patients undergoing CEA with general anesthesia (n=1040)
Number of subjects: 1151
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial nerve injury (CNI) in patients undergoing CEA with local anesthesia (n=111)
Number of subjects: 1151
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of CNI at 1 month
Number of subjects: 1151
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolution of CNI at 1 year
Number of subjects: 1151
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQOL evaluation for patients with CNI
Number of subjects: 1151
Study 25770984 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty eating/swallowing in patients with CNI
Number of subjects: 1151
Study 23939841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment manoeuvre (two manual inflations to a maximum pressure of 60 cmH2 O)
Number of subjects: 76
Study 23939841 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (passive decompression via open operative ports)
Number of subjects: 76
Study 19765239 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with vibration (VIB)
Number of subjects: 18
Study 19765239 — intervention group
Group type: COMPARATOR
Intervention: Resistance training alone (CON)
Number of subjects: 18
Study 18250271 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-9803 (0.05 mg)
Number of subjects: 154
Study 18250271 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-9803 (0.5 mg)
Number of subjects: 154
Study 18250271 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-9803 (1.25 mg)
Number of subjects: 154
Study 18250271 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-9803 (5.0 mg)
Number of subjects: 154
Study 18250271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 16488388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + videotape feedback of performance (PER)
Number of subjects: 77
Study 16488388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + videotape feedback of audience responses (AUD)
Number of subjects: 77
Study 16488388 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + no feedback (EXP)
Number of subjects: 77
Study 16488388 — intervention group
Group type: COMPARATOR
Intervention: Credible placebo treatment (PLA)
Number of subjects: 77
Study 12741878 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance back extension exercise on a 45 degrees Roman chair once weekly for 12 weeks, one set of 8‐20 dynamic repetitions to volitional exhaustion using hand‐held metal plates for additional resistance
Number of subjects: 15
Study 12741878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 15
Study 10834689 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesylate (2 mg/kg/hr)
Number of subjects: 34
Study 10834689 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 mL/hr; control group)
Number of subjects: 34
Study 9003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 797
Study 9003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-type incentive
Number of subjects: 797
Study 9003108 — intervention group
Group type: COMPARATOR
Intervention: Both educational brochure and incentive
Number of subjects: 797
Study 9003108 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 797
Study 9003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure (for individuals who had not accepted immunization in the prior year)
Number of subjects: 797
Study 1352563 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg
Number of subjects: 24
Study 1352563 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg
Number of subjects: 24
Study 1352563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6716470 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape about smoking
Number of subjects: 0
Study 6716470 — intervention group
Group type: COMPARATOR
Intervention: Videotape on a different health topic
Number of subjects: 0
Study 30568303 — intervention group
Group type: EXPERIMENTAL
Intervention: APVAC1 vaccine derived from unmutated antigens
Number of subjects: 15
Study 30568303 — intervention group
Group type: EXPERIMENTAL
Intervention: APVAC2 vaccine targeting neoepitopes
Number of subjects: 15
Study 30568303 — intervention group
Group type: EXPERIMENTAL
Intervention: GAPVAC approach with poly-ICLC and GM-CSF as adjuvants
Number of subjects: 15
Study 29857876 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy program (10 sessions, once weekly)
Number of subjects: 28
Study 29857876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 27097076 — intervention group
Group type: EXPERIMENTAL
Intervention: A. dracunculus (1000 mg) before breakfast and dinner for 90 days
Number of subjects: 24
Study 27097076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24447459 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle counseling to parents of overweight children
Number of subjects: 637
Study 24447459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study 23138652 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoamniotic shunting using a double-basket catheter (1.47 mm diameter)
Number of subjects: 24
Study 20467301 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prescription throughout the study
Number of subjects: 119
Study 20467301 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise prescription after completing cancer treatment
Number of subjects: 119
Study 20467301 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study 17879957 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 303
Study 17879957 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 303
Study 17879957 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose concentrations at 120 min of the OGTT
Number of subjects: 303
Study 17879957 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose area below fasting values (GABF) at the end of the OGTT
Number of subjects: 303
Study 15961983 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg twice daily injected subcutaneously
Number of subjects: 628
Study 12503709 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIMV)
Number of subjects: 36
Study 12503709 — intervention group
Group type: COMPARATOR
Intervention: Sham NIMV
Number of subjects: 36
Study 9622312 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional folic acid containing multivitamin supplementation
Number of subjects: 0
Study 7857350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (800 mg orally, twice daily) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Number of subjects: 137
Study 7857350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one sachet) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Number of subjects: 137
Study 2493433 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 960
Study 2493433 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation
Number of subjects: 960
Study 2493433 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant tamoxifen
Number of subjects: 960
Study 196167 — intervention group
Group type: EXPERIMENTAL
Intervention: Seda-Kneipp (a compound preparation of valerian and hops)
Number of subjects: 0
Study 196167 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with 'strong' sleeping pills followed by 'weak' sleeping pills
Number of subjects: 0
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover anastomosis (CA) flaps
Number of subjects: 84
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP-1 (1 perforator) flaps
Number of subjects: 84
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-TRAM flaps
Number of subjects: 84
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP-2 (2 perforators) flaps
Number of subjects: 84
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-TRAM and DIEP-2 flaps
Number of subjects: 84
Study 31232810 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP-1 flaps
Number of subjects: 84
Study 30145946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 45 days
Number of subjects: 12019
Study 30145946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12019
Study 26896073 — intervention group
Group type: EXPERIMENTAL
Intervention: True Waiguan acupuncture
Number of subjects: 24
Study 26896073 — intervention group
Group type: COMPARATOR
Intervention: Sham Waiguan acupuncture
Number of subjects: 24
Study 26896073 — intervention group
Group type: COMPARATOR
Intervention: True needling of a nonacupoint
Number of subjects: 24
Study 26896073 — intervention group
Group type: COMPARATOR
Intervention: Sham needling of a nonacupoint
Number of subjects: 24
Study 24277115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 77
Study 24277115 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation‐guided injection
Number of subjects: 77
Study 23143689 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based pharmacist intervention; education and counseling on medication adherence.
Number of subjects: 95
Study 23143689 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group); no specific intervention mentioned.
Number of subjects: 95
Study 18996225 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 6 months
Number of subjects: 252
Study 18996225 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 252
Study 17891537 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 52
Study 17891537 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 30 mg
Number of subjects: 52
Study 17891537 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52
Study 17891537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 15302778 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment
Number of subjects: 9974
Study 15302778 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of UFH (>5000 U, or up to 90 U/kg)
Number of subjects: 9974
Study 15302778 — intervention group
Group type: EXPERIMENTAL
Intervention: UFH weight‐indexed dose
Number of subjects: 9974
Study 12670035 — intervention group
Group type: EXPERIMENTAL
Intervention: IVECG signal conducted from the guide wire (group G)
Number of subjects: 60
Study 12670035 — intervention group
Group type: EXPERIMENTAL
Intervention: IVECG signal conducted from the transduction probe (group T)
Number of subjects: 60
Study 12670035 — intervention group
Group type: COMPARATOR
Intervention: Group G (guide wire)
Number of subjects: 60
Study 12670035 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (transduction probe)
Number of subjects: 60
Study 9066028 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP conjugated to an outer membrane protein complex (PRP-OMP)
Number of subjects: 30
Study 9066028 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP oligomers conjugated to CRM197 (HbOC)
Number of subjects: 30
Study 9066028 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 8200218 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone 12 hours before surgical procedure
Number of subjects: 60
Study 8200218 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone 24 hours before surgical procedure
Number of subjects: 60
Study 8200218 — intervention group
Group type: COMPARATOR
Intervention: Placebo 24 hours before interruption of pregnancy
Number of subjects: 60
Study 3300475 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation alone (progressive muscle relaxation and focused breathing)
Number of subjects: 30
Study 3300475 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation combined with mental imagery of the immune system
Number of subjects: 30
Study 3300475 — intervention group
Group type: COMPARATOR
Intervention: Vigilance task (alertness or mild arousal control)
Number of subjects: 30
Study 29049072 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB with 5 mL of 0.5% mepivacaine
Number of subjects: 52
Study 29049072 — intervention group
Group type: COMPARATOR
Intervention: SGB with 5 mL of normal saline
Number of subjects: 52
Study 28550240 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 AA genotype
Number of subjects: 862
Study 25594610 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (0.1%) cream (BMVc)
Number of subjects: 17
Study 25594610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1%) ointment (TACo)
Number of subjects: 17
Study 23984572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax-AWS
Number of subjects: 60
Study 23984572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60
Study 23984572 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 21911872 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home exercise program (TG)
Number of subjects: 35
Study 21911872 — intervention group
Group type: COMPARATOR
Intervention: Phone calls twice per week for 12 weeks (CG)
Number of subjects: 35
Study 19042328 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational Therapy (PET)
Number of subjects: 88
Study 19042328 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 88
Study 16570038 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with CPT-11 (irinotecan)
Number of subjects: 42
Study 14642412 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 26
Study 14642412 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 26
Study 14642412 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 26
Study 14642412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 11113417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 11113417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit arteries with abnormal flow
Number of subjects: 0
Study 8953357 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant behavioural management strategies (Condition 1)
Number of subjects: 0
Study 8953357 — intervention group
Group type: COMPARATOR
Intervention: Mutual goal setting (Condition 2)
Number of subjects: 0
Study 8953357 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Condition 3)
Number of subjects: 0
Study 8169547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar range of motion examination using the Orthoranger II digital inclinometer, conducted twice by each examiner (four times total per subject)
Number of subjects: 28
Study 8169547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar flexion measurement
Number of subjects: 28
Study 8169547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extension measurement
Number of subjects: 28
Study 8169547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar lateral flexion measurement
Number of subjects: 28
Study 3286342 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined carbohydrate diet
Number of subjects: 10
Study 3286342 — intervention group
Group type: COMPARATOR
Intervention: Refined carbohydrate diet
Number of subjects: 10
Study 29975125 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Vibration with Blood Flow Restriction (LV + BFR)
Number of subjects: 12
Study 29975125 — intervention group
Group type: COMPARATOR
Intervention: Local Vibration (LV)
Number of subjects: 12
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 0
Study 27958255 — intervention group
Group type: COMPARATOR
Intervention: Nonobese group
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of egg
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of bovine liver
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of mushroom
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of red meat
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI correlation with vitB12
Number of subjects: 0
Study 27958255 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance correlation with vitB12
Number of subjects: 0
Study 24366167 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 466
Study 24366167 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 466
Study 23232158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (virtual reality + modified constraint-induced movement therapy)
Number of subjects: 32
Study 23232158 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy in a virtual environment
Number of subjects: 32
Study 23232158 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 19944596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine
Number of subjects: 16
Study 19944596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 16
Study 17437361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg IV initial dose then 50 mg IV every 12 h)
Number of subjects: 0
Study 17437361 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500 mg IV every 6 h)
Number of subjects: 0